Royalty Report: Drugs, Pharmaceuticals, Research – Collection: 5746


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Research
  • Stem cells
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5746

License Grant
Israeli University hereby grants to Licensee an exclusive, worldwide, royalty-bearing license under the Licensor Technology and Licensor's interest in the Joint Technology solely to research, develop, make, have made, use, offer for sale, sell, have sold, import and export Licensed Products.

Technology relating to processes for the transformation of bone marrow and cord blood stem cells into neuron-like and glial-like cells developed at an University in Israel are being licensed (exclusive, worldwide, and royalty-bearing) to a U.S. company by a commercial arm of the university.

License Property
The original agreement dated  July 8, 2004, to acquire certain stem cell technology for the development of novel cell therapies for neurodegenerative diseases, particularly, Parkinson's disease, based on the acquired technology and research to be conducted and funded by the Israeli Licensor.
Field of Use
The rights granted apply to neurodegenerative diseases.

IPSCIO Record ID: 204653

License Grant
Israeli University granted to Licensee an exclusive license to (i) the inventions, know-how and results made with respect to the stem cell technology developed by the team led in the course of the performance of the research, and the patents and pending patent applications owned by University, and (ii) the results of further research to be performed by the same team on the development of the stem cell technology.
License Property
The inventions, know-how and results made with respect to the stem cell technology relating to processes for the transformation of bone marrow and cord blood stem cells into neuron-like and glial-like cells.
Field of Use
This agreement pertains to stem cell technology.

IPSCIO Record ID: 3624

License Grant
The Israeli Licensor hereby grants to the Licensee, an exclusive license to exploit in any manner and for any and all purposes the Patent, including the right to grant sublicenses, make, have made, use, market and sell the Products.
License Property
The Company entered into a License Agreement to acquire a License of stem cell expansion technology related to bone marrow transplants. The Company received an exclusive, worldwide License to use the technology over the life of the related patent. The License grants exclusivity over all products, uses and related intellectual property, and grants the Company the right to enter into sub-Licenses. This technology, if fully developed, will offer novel solutions to make procedures like bone marrow transplants and other methods of cell therapy more accessible to patients suffering from leukemia, lymphoma, myeloma and a broad range of complicated diseases and disorders.

IPSCIO Record ID: 1065

License Grant
In March 1992, Licensee entered into a License Agreement with the Licensor, as contemplated by a Research Agreement executed in August 1989 relating to the ex vivo production of human cells. Pursuant to this License Agreement, as amended: (i) we acquired exclusive worldwide license rights to the patents and know-how for the production of blood cells and bone marrow cells as described in the Licensor's research project or which resulted from certain further research conducted through December 1994; and (ii) we are obligated to pay a royalty based on the net sales of products which are covered by the patents.
Field of Use
The rights granted apply to the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.